Literature DB >> 2939153

Inactivation of quinolone by feces.

J J van Saene, H K van Saene, C F Lerk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2939153     DOI： 10.1093/infdis/153.5.999

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  9 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

Review 2.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

3.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Effect of oral ofloxacin on fecal bacteria in human volunteers.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

5.  Degradation of ciprofloxacin by basidiomycetes and identification of metabolites generated by the brown rot fungus Gloeophyllum striatum.

Authors:  H G Wetzstein; M Stadler; H V Tichy; A Dalhoff; W Karl
Journal:  Appl Environ Microbiol       Date:  1999-04       Impact factor: 4.792

Review 6.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Authors:  G H Talbot; P A Cassileth; L Paradiso; R Correa-Coronas; L Bond
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Effect of parenteral fluoroquinolone administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.

Authors:  Curtis J Donskey; Marion S Helfand; Nicole J Pultz; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.